Adlai Nortye Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Yang Lu
- Full Time Employees
- 109
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 77 Robinson Road, #20-01, Robinson 77 Singapore Singapore 068896
- IPO Date
- Sep 29, 2023
- CIK
- 0001944552
- Website
- adlainortye.com
- Similar Companies
- Business
- Adlai Nortye Ltd. is a global clinical-stage biopharmaceutical company specializing in the discovery and development of innovative targeted and immune-modulating cancer therapies. Founded in 2016 and headquartered in Hangzhou, China, with global R&D centers in the United States and China, the company advances a robust oncology pipeline including AN8025, a trifunctional fusion protein modulating T cells and antigen-presenting cells; AN9025, an oral small molecule pan-RAS(ON) inhibitor targeting a broad spectrum of RAS mutations; AN4005, an oral PD-L1 inhibitor; and AN2025 (Buparlisib), a pan-PI3K inhibitor in a registrational Phase 3 trial for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The company also develops AN0025 (Palupiprant) and AN4035 (a CEACAM5 antibody-drug conjugate). Adlai Nortye operates as an investment holding company incorporated in the Cayman Islands. In recent developments, Adlai Nortye expanded its technical and commercial partnership with Xiamen Biotime Biotechnology Co., Ltd. to facilitate the global development and commercialization of oncology products, including AN4005 and AN3025. The company appointed Roger Sawhney, M.D. to its Board of Directors in 2024 and named Tse M.D., Ph.D. as Head of Research and Development, bolstering leadership expertise. In 2024, clinical trial advancements included promising safety and efficacy results for AN4005, with a complete response reported, and plans to report Phase 3 overall survival data for buparlisib in early 2025. The company bolstered its financial position with $98 million in cash as of mid-2024, supporting ongoing R&D and operations. Adlai Nortye targets oncology patients globally with a focus on developing novel immuno-oncology and targeted therapies across a range of solid tumors and hematologic malignancies. The company maintains strategic research collaborations and clinical operations spanning the U.S. and China to drive innovation and regulatory milestone achievements for its pipeline candidates. The enterprise emphasizes advancing differentiated novel molecules with potential first- or best-in-class profiles aimed at transforming cancer treatment paradigms. This profile encapsulates Adlai Nortye’s comprehensive product portfolio, key strategic partnerships, leadership appointments, clinical trial progression, and financial health, reflecting its position as an emerging player in the global oncology biopharmaceutical sector.
Company News
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Stock Has Consensus Target Price of $29.50 According to Analysts
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High?
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
Adlai Nortye (ANL) to Announce Quarterly Earnings on Thursday
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know
Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Outperforming Other Medical Stocks This Year?
Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year?
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing